We reached a milestone today with the first participant randomisation visit for the ISAP trial. ISAP investigates the effect of oral semaglutide compared with placebo on the brain in individuals at risk for Alzheimer’s disease.
Thank you to the study participants, Oxford Health NIHR Clinical Research Facility, Dementias Platform UK, Oxford Health Biomedical Research Centre, and the funder Novo Nordisk who supported this investigator initiated study.